Development and Evaluation of Patient Education and Counselling Intervention for Cardiovascular Patients recovered from COVID-19

Development and Evaluation of Pharmaceutical Care Intervention for Post COVID-19 Cardiovascular Patients

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/053042

Enrollment

160

Registered

2023-05-23

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I00-I99- Diseases of the circulatory system

Interventions

Intervention1: Pharmaceutical Care: Patient Information Leaflet, Patient Counselling by Pharmacist and Resolve Drug Related Problems. Duration: At the time of enrollment, first follow up at 3 months a

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with cardiovascular disease after recovered from COVID-19

Exclusion criteria

Exclusion criteria: 1. Patients having cardiovascular disease before COVID-19 exposure 2. Pregnant women and immunocompromised patients 3. Patients who are not willing to participate in the study

Design outcomes

Primary

Measure	Time frame
To assess the impact of pharmaceutical care on humanistic and clinical outcomes in patients recovered from COVID-19Timepoint: At the completion of study	—

Secondary

Measure	Time frame
1. To analyze the risk factors associated with cardiovascular problems in patients recovered from COVID-19 2. To identify and resolve drug-related problems in patients recovered from COVID-19 Timepoint: At the completion of study	—

Countries

India

Contacts

Public ContactDr Kanav Khera

School of Pharmaceutical Sciences, Lovely Professional University

navneet.pharma@gmail.com9041612292

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026